DLL3 and neoplasm: Learnings from this approach have led to the development of AMG757, a DLL3-CD3 BiTE molecule in Phase I clinical testing, where utilization of a more tumor selective anchor protein, DLL3, raises hopes for reduced toxicity (https://clinicaltrials.gov/ct2/show/NCT03319940).